Arbele develops a robust and high throughput target discovery platform from preclinical to translational studies
CDH17 detects major types of malignant solid tumors
The cancer target, CDH17, plays important role in cancer progression and metastasis, which has been found in major cancer types including:
1. CDH17 is associated with major types of gastrointestinal malignancies.
2. Arbele’s most advanced clinical product targets liver, stomach and metastatic colon cancers, and may be effective in other cancer types.
3. In addition to CDH17, we are developing drug candidates that target other tumor associated antigens.
Anti-CDH17 kills cancer cells and inhibits tumor metastasis
(A) CDH17 RNAmir causes cancer cell death
(B) CDH17 mAb prevents lung metastasis
Chimeric Antigen Receptor (CAR) technology directs T and NK (natural killer) cells to recognize cancer cells based on expression of specific cell surface proteins.Learn More
The use of bispecific antibodies, targeting two tumor antigens for cancer treatment. This approach evolves to BiTE therapeutics, a bi-specific mAb that forms a link between tumor and T cells, causing cancer cell death.Learn More
Using high-throughput and cutting-edge DNA sequencing technology, we can identify the oncogenes and mutations unique in patient's samples - tumor and liquid biopsies for early diagnosis and precision treatments.Learn More